Adlai Nortye Group
ANLNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $9.96 Prior regular-session close from the quote source.
- $9.76–$11.21 Regular-session low and high so far today.
- 195.9K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $0.88–$17.25 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own ANL if its pharma pipeline produces partnerable or approvable evidence before dilution overwhelms shareholders.
ANL price history
Loading recent earnings…
Investment thesis
What must happen next
Cash discipline and portfolio prioritization must carry ANL to value-inflecting clinical, regulatory, or partnering events without forcing distressed dilution.HoldingMateriality: High
FY2024 year-end cash was $60.9 million, giving ANL some optionality to fund development. If runway reaches a validating event, shareholders keep meaningful upside; if not, financing terms can transfer value away from current owners.
Watch: A lead clinical program requires an additional pivotal or bridging study before any approval or partnership decision.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2024 year-end cash was $60.9 million, giving ANL some optionality to fund development.
Open source ↗Near-term monetization depends on licensing, collaboration, or milestone economics rather than a repeatable commercial sales engine.StrengtheningMateriality: High
Annual revenue was $45.7 million in FY2021 but only $5.0 million in FY2023, consistent with episodic monetization rather than steady product demand. If ANL can turn pipeline assets into non-dilutive partner revenue, burn becomes fundable; if not, revenue will not support the development plan.
Watch: A prospective licensing partner declines to proceed after reviewing clinical data.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Annual revenue was $45.7 million in FY2021 but only $5.0 million in FY2023, consistent with episodic monetization rather than steady.
Open source ↗Management must keep development spending concentrated enough that losses narrow or are externally funded, rather than letting a broad pipeline consume the balance sheet.HoldingMateriality: Medium
FY2024 annual operating income was negative $52.9 million, improved from negative $72.6 million in FY2023. Loss discipline extends option value; uncontrolled spend increases the odds that shareholders fund science at unfavorable prices.
Watch: ANL initiates multiple late-stage trials at once without a partner funding a material portion of costs.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2024 annual operating income was negative $52.9 million, improved from negative $72.6 million in FY2023.
Open source ↗ANL’s investment case requires preserving balance-sheet option value so that clinical decisions are made from strength rather than creditor or liquidity pressure.HoldingMateriality: Medium
FY2024 equity was positive $25.5 million, versus negative $241.3 million in FY2022. A healthier balance sheet lets ANL wait for better data or partner terms; a weakening one can force value-destructive capital raises.
Watch: New debt, preferred securities, warrants, or payables are used to fund development in ways that subordinate common shareholders.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2024 equity was positive $25.5 million, versus negative $241.3 million in FY2022.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Cash discipline and portfolio prioritization must carry ANL to value-inflecting clinical, regulatory, or partnering events without forcing distressed dilution. If runway reaches a validating event, shareholders keep meaningful upside; if not, financing terms can transfer value away from current owners.
Near-term monetization depends on licensing, collaboration, or milestone economics rather than a repeatable commercial sales engine. If ANL can turn pipeline assets into non-dilutive partner revenue, burn becomes fundable; if not, revenue will not support the development plan.
Management must keep development spending concentrated enough that losses narrow or are externally funded, rather than letting a broad pipeline consume the balance sheet. Loss discipline extends option value; uncontrolled spend increases the odds that shareholders fund science at unfavorable prices.
ANL’s investment case requires preserving balance-sheet option value so that clinical decisions are made from strength rather than creditor or liquidity pressure. A healthier balance sheet lets ANL wait for better data or partner terms; a weakening one can force value-destructive capital raises.
All standing thesis claims
Original report summary
its pharma pipeline produces partnerable or approvable evidence before dilution overwhelms shareholders.
Bull case and bear case
Bull case and bear case for Adlai Nortye Group
Where the evidence on Adlai Nortye Group stands: Holding on the latest evidence (Oct 15, 2026). Of its 4 thesis points, 1 strengthening and 3 holding.
Bull case: what the evidence supports
Cash discipline and portfolio prioritization must carry ANL to value-inflecting clinical, regulatory, or partnering events without forcing distressed dilution.
Near-term monetization depends on licensing, collaboration, or milestone economics rather than a repeatable commercial sales engine.
Management must keep development spending concentrated enough that losses narrow or are externally funded, rather than letting a broad pipeline consume the balance sheet.
ANL’s investment case requires preserving balance-sheet option value so that clinical decisions are made from strength rather than creditor or liquidity pressure.
Bear case: what would count against it
A lead clinical program requires an additional pivotal or bridging study before any approval or partnership decision.
A prospective licensing partner declines to proceed after reviewing clinical data.
ANL initiates multiple late-stage trials at once without a partner funding a material portion of costs.
Thesis-Break Engine
What has broken in Adlai Nortye Group’s thesis
Each break OptimistFi flagged on Adlai Nortye Group, dated — with what has historically followed the same kind of break across the market, not a forecast for Adlai Nortye Group.
- Sharp drawdowncondition set before this filing
Across all companies, this kind of break has happened 15,428 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedREPORT OF FOREIGN PRIVATE ISSUER.
Adlai Nortye Group filed an SEC report on 2026-09-30: REPORT OF FOREIGN PRIVATE ISSUER. It is a dated development that tests the current thesis.
- MixedREPORT OF FOREIGN PRIVATE ISSUER.
Adlai Nortye Group filed an SEC report on 2026-09-08: REPORT OF FOREIGN PRIVATE ISSUER. It is a dated development that tests the current thesis.
- MixedCURRENT REPORT.
Adlai Nortye Group filed an SEC report on 2026-08-26: CURRENT REPORT. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A lead clinical program requires an additional pivotal or bridging study before any approval or partnership decision.
- A prospective licensing partner declines to proceed after reviewing clinical data.
- ANL initiates multiple late-stage trials at once without a partner funding a material portion of costs.
- New debt, preferred securities, warrants, or payables are used to fund development in ways that subordinate common shareholders.
ANL news
Loading headlines…
Financial statements
ANL income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
ANL: quick answers
- What is ANL's short interest?
- As of October 30, 2026, 5.8M ANL shares were sold short, up 13.8% from the count before. At the stock's average daily volume that is 27 days to cover. FINRA publishes the count twice a month. ANL short interest history